For instance, agents targeting IL-6, IL-6R, and JAK/STAT3 signaling pathways downstream of IL-6 have been approved by the US Food and Drug Administration (FDA) in myeloproliferative diseases and autoimmune disorders in order to suppress the FAP + CAF-induced proinflammatory cytokines and pro-angiogenic factors, which increase cancer cell proliferation and metastasis and negatively regulate T cell and NK cytotoxic activity [136]. This evidence concerns the gene FAP and cancer.